Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database
Background: Among antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs) are particularly expected to increase the risk of hypertensive disorders of pregnancy (HDP) with regard to their biological mechanism. We aimed to evaluate the association between prenatal exposure to SNRI and HDP.
Methods: In EFEMERIS, a French database including pregnant women covered by the French Health Insurance System of Haute-Garonne (2004–2019), we compared the incidence of HDP among women exposed to SNRI monotherapy during the first trimester of pregnancy to the incidence among 2 control groups: (1) women exposed to selective serotonin reuptake inhibitor (SSRI) monotherapy during the first trimester and (2) women not exposed to antidepressants during pregnancy. We conducted crude and also multivariate logistic regressions.
Results: Of the 156,133 pregnancies, 143,391 were included in the study population, including 210 (0.1%) in the SNRI group, 1,316 (0.9%) in the SSRI group, and 141,865 (98.9%) in the unexposed group. After adjustment for depression severity and other mental conditions, the risk of HDP was significantly higher among women exposed to SNRIs (n = 20; 9.5%) compared to women exposed to SSRIs (n = 72; 5.5%; adjusted odds ratio [aOR] [95% CI] = 2.32 [1.28–4.20]) and to unexposed women (n = 6,224; 4.4%; aOR [95% CI] = 1.89 [1.13–3.18]).
Conclusion: This study indicated an increased risk of HDP in women treated with SNRIs versus women treated with SSRIs.
J Clin Psychiatry 2023;84(4):22m14734
Author affiliations are listed at the end of this article.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Yin X, Sun N, Jiang N, et al. Prevalence and associated factors of antenatal depression: systematic reviews and meta-analyses. Clin Psychol Rev. 2021;83:101932. PubMedCrossRef
Gorman JR, Kao K, Chambers CD. Breastfeeding among women exposed to antidepressants during pregnancy. J Hum Lact. 2012;28(2):181–188. PubMedCrossRef
Charlton RA, Jordan S, Pierini A, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG. 2015;122(7):1010–1020. PubMedCrossRef
Zoega H, Kieler H, Nørgaard M, et al. Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden. PLoS One. 2015;10(12):e0144474. PubMedCrossRef
Molenaar NM, Bais B, Lambregtse-van den Berg MP, et al. The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 2020;264:82–89. PubMedCrossRef
Hurault-Delarue C, Lacroix I, Bénard-Laribière A, et al. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019;269(7):841–849. PubMedCrossRef
Andersen J, Kristensen AS, Bang-Andersen B, et al. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009;(25):3677–3692. PubMedCrossRef
Gonzalez C, Cruz MA, Sepulveda WH, et al. Effects of serotonin on vascular tone of isolated human placental chorionic veins. Gynecol Obstet Invest. 1990;29(2):88–91. PubMedCrossRef
Steele SC, Warren AY, Johnson IR. Effect of the vascular endothelium on norepinephrine-induced contractions in uterine radial arteries from the nonpregnant and pregnant human uterus. Am J Obstet Gynecol. 1993;168(5):1623–1628. PubMedCrossRef
Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237–e260. PubMedCrossRef
Olié V, Moutengou E, Grave C, et al. Prevalence of hypertensive disorders during pregnancy in France (2010–2018): The Nationwide CONCEPTION Study. J Clin Hypertens (Greenwich). 2021;23(7):1344–1353. PubMedCrossRef
Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019;7:2050312119843700. PubMedCrossRef
Brown MA, Magee LA, Kenny LC, et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43. PubMedCrossRef
Steegers EAP, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376(9741):631–644. PubMedCrossRef
Newport DJ, Hostetter AL, Juul SH, et al. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. J Clin Psychiatry. 2016;77(11):1538–1545. PubMedCrossRef
Bernard N, Forest JC, Tarabulsy GM, et al. Use of antidepressants and anxiolytics in early pregnancy and the risk of preeclampsia and gestational hypertension: a prospective study. BMC Pregnancy Childbirth. 2019;19(1):146. PubMedCrossRef
Galbally M, Watson SJ, Spigset O. Depression and antidepressant treatment in the development of hypertensive disorders of pregnancy: results from a prospective cohort study. Aust N Z J Psychiatry. 2023;57(4):520–527. PubMedCrossRef
Avalos LA, Chen H, Li DK. Antidepressant medication use, depression, and the risk of preeclampsia. CNS Spectr. 2015;20(1):39–47. PubMedCrossRef
Shay M, MacKinnon AL, Metcalfe A, et al. Depressed mood and anxiety as risk factors for hypertensive disorders of pregnancy: a systematic review and meta-analysis. Psychol Med. 2020;50(13):2128–2140. PubMedCrossRef
Palmsten K, Huybrechts KF, Michels KB, et al. Antidepressant use and risk for preeclampsia. Epidemiology. 2013;24(5):682–691. PubMedCrossRef
Yang LY, Lin FJ, Katz AJ, et al. Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy. Am J Obstet Gynecol. 2021;225(6):672.e1–672.e11. PubMedCrossRef
Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65(8):839–846. PubMedCrossRef
Damase-Michel C, Lacroix I, Hurault-Delarue C, et al. Évaluation des médicaments chez la femme enceinte: à propos de la base de données française EFEMERIS. (Drug in pregnancy: studies in the French database EFEMERIS). Therapie. 2014;69(1):91–100. PubMedCrossRef
Ministère du Travail, de L’Emploi et de la Santé. Arrêté du 30 septembre 2011 Portant radiation de spécialités pharmaceutiques de la liste mentionnée au premier alinéa de l’article l. 162–17 du code de la sécurité sociale. Journal officiel électronique authentifié. No. 0231. Published October 5, 2011. https://www.legifrance.gouv.fr/download/pdf?id=3EIIt1yXfA7isPSYGTp531GFxjp-OhM2wb5Aj0O8TSo=.
Toh S, Mitchell AA, Louik C, et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry. 2009;166(3):320–328. PubMedCrossRef
Roberts CL, Bell JC, Ford JB, et al. The accuracy of reporting of the hypertensive disorders of pregnancy in population health data. Hypertens Pregnancy. 2008;27(3):285–297. PubMedCrossRef
Klemmensen AK, Olsen SF, Osterdal ML, et al. Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. Am J Epidemiol. 2007;166(2):117–124. PubMedCrossRef
Palmsten K, Huybrechts KF, Kowal MK, et al. Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf. 2014;23(6):646–655. PubMedCrossRef
Yasmeen S, Romano PS, Schembri ME, et al. Accuracy of obstetric diagnoses and procedures in hospital discharge data. Am J Obstet Gynecol. 2006;194(4):992–1001. PubMedCrossRef
Boucheron P, Lailler G, Moutengou E, et al. Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study. Eur Heart J. 2022;43(35):3352–3361. PubMedCrossRef
Committee Opinion No 700: methods for estimating the due date. Obstet Gynecol. 2017;129(5):e150–e154. PubMedCrossRef
Bartsch E, Medcalf KE, Park AL, et al; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. PubMedCrossRef
Li Z, Ye R, Zhang L, et al. Folic acid supplementation during early pregnancy and the risk of gestational hypertension and preeclampsia. Hypertension. 2013;61(4):873–879. PubMedCrossRef
Parant O, Deudon R, Bennevent J, et al. Utilisation des inhibiteurs des canaux calciques (ICC) en ocolyses en France et à l’étranger. (Use of calcium channel blockers [CCB] for tocolysis in France and abroad). J Gynecol Obstet Biol Reprod (Paris). 2015;44(4):312–323. PubMedCrossRef
Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66(3):305–315. PubMedCrossRef
Zakiyah N, Ter Heijne LF, Bos JH, et al. Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study. BMC Pregnancy Childbirth. 2018;18(1):187. PubMedCrossRef
Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2022;226(2S):S1211–S1221. PubMedCrossRef
Adhikari K, Patten SB, Lee S, et al. Adherence to and persistence with antidepressant medication during pregnancy: does it differ by the class of antidepressant medication prescribed? Can J Psychiatry. 2019;64(3):199–208. PubMedCrossRef
Blondel B, Coulm B, Bonnet C, et al; National Coordination Group of the National Perinatal Surveys. Trends in perinatal health in metropolitan France from 1995 to 2016: results from the French National Perinatal Surveys. J Gynecol Obstet Hum Reprod. 2017;46(10):701–713. PubMedCrossRef
Slomian J, Honvo G, Emonts P, et al. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health (Lond). 2019;15:1745506519844044. PubMedCrossRef
Reminick A, Cohen S, Einarson A. Managing depression during pregnancy. Womens Health (Lond). 2013;9(6):527–535. PubMedCrossRef